Published in final edited form as:

Cancer Res. 2009 October 15; 69(20): 8111–8119. doi:10.1158/0008-5472.CAN-09-1057.

The Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination

Xin-Zi Chi^{1,*}, Jiyeon Kim^{1,7,*}, Yong-Hee Lee^{1,*}, Jung-Won Lee¹, Kyeong-Sook Lee¹, Heejun Wee¹, Wun-Jae Kim², Woo-Yoon Park³, Byung-Chul Oh⁴, Gary S. Stein⁵, Yoshiaki Ito⁶, Andre J. van Wijnen⁵, and Suk-Chul Bae¹

¹Department of Biochemistry, Chungbuk National University, Cheongju 361-763, South Korea

²Department of Urology, College of Medicine, Institute of Tumor Research, Chungbuk National University, Cheongju 361-763, South Korea

³Department of Radiation Oncology, Chungbuk National University College of Medicine, Cheongju 361-763, South Korea

⁴Lee Gil Ya Cancer and Diabetes Institute, Gachon University of Medicine and Science, Songdo-dong, Incheon 406-840, South Korea

⁵Department of Cell Biology and Cancer Center, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA

⁶Institute of Molecular and Cell Biology, 61 Biopolis Drive, proteos, Singapore 138673, Singapore

Abstract

The p14^{ARF}-MDM2-p53 pathway constitutes an effective mechanism for protecting cells from oncogenic stimuli like activated *Ras* and *Myc*. Importantly, *Ras* activation induces p14^{ARF} and often occurs earlier than p53 inactivation during cancer development. Here we show that RUNX3, a tumor suppressor in various tumors including stomach, bladder, colon and lung, is stabilized by *Ras* activation through the p14^{ARF}-MDM2 signaling pathway. RUNX3 directly binds MDM2 through its Runt-related DNA binding domain. MDM2 blocks RUNX3 transcriptional activity by interacting with RUNX3 through an acidic domain adjacent to the p53 binding domain of MDM2, and ubiquitinates RUNX3 on key lysine residues to mediate nuclear export and proteasomal degradation. Our data indicate that the lineage-specific tumor suppressor RUNX3 and the ubiquitous p53 protein are both principal responders of the p14^{ARF}-MDM2 cell surveillance pathway that prevents pathological consequences of abnormal oncogene activation.

Keywords

RUNX3; Ras; p14ARF; MDM2; ubiquitination

INTRODUCTION

Deregulation of proliferation in mammalian cancer cells involves the synergistic induction of pro-mitogenic regulatory pathways and inactivation of anti-mitogenic factors. The regulatory functions of the two classical tumor suppressors, p53 and retinoblastoma protein

Corresponding authors: Suk-Chul Bae: scbae@chungbuk.ac.kr, Andre J. van Wijnen: Andre.VanWijnen@umassmed.edu.

*X-Z Chi, J Kim and Y-H Lee contributed equally.

⁷Present address: Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC USA

(pRB), are well understood. Accumulating evidence indicates that the cell fate-determining Runt-related (RUNX) transcription factors play complementary biological roles to the p53 and pRB tumor suppressors in both hematopoietic and non-hematopoietic cancers, including cancers of the gastro-intestinal tract, as well as breast and prostate (1). While tumor-related modifications in the p53-pRB network are evident in the same spectrum of tumors, a fundamental question is whether and how RUNX responsive regulatory pathways are mechanistically linked to p53-pRB dependent cellular surveillance mechanisms.

Several oncogenic and DNA damage related pathways converge on p53, which is the key effector of a critical checkpoint that arrests the cell cycle (2). The p53 protein is normally labile and maintained at very low levels. Mouse Double Minute 2 (MDM2) (HDM2 in human, referred to here as MDM2), a RING-finger E3-ubiquitin ligase, plays an essential role in p53 degradation by promoting ubiquitination of p53 which induces nuclear export and proteasomal degradation of p53 (3). The stabilization of p53 and its activation is mediated by the p14^{ARF}(human)-p19^{ARF}(mouse)/MDM2 pathway in response to oncogenic stimulation or by DNA damage dependent activation through the ATM/ATR kinase pathway (4). p14^{ARF} inhibits the ubiquitin ligase activity of MDM2 by binding to a central region of MDM2. MDM2 can also inhibit p53-mediated transcriptional activation in a ubiquitination independent manner (5). MDM2 also has p53-independent functions as reflected by elevation of MDM2 activity in patients with p53 mutations (6,7) and MDM2-mediated growth advantage in the absence of p53 (8,9).

RUNX transcription factors play pivotal roles in normal development and neoplasia (10). Deregulation of the biological functions of the three human *RUNX* family genes, *RUNX1/AML1*, *RUNX2/CBFA1* and *RUNX3/PEBP2αC* (11) contributes to cancer. *RUNX1* is required for hematopoiesis and is genetically altered in leukemia (12–14). *RUNX2* is linked to osteogenesis (15,16) and alterations in human *RUNX2* levels are associated with cleidocranial dysplasia (17,18) and osteosarcoma (19). *RUNX3* is required for the development of CD8-lineage T cells (20,21) and TrkC-dependent dorsal root ganglion neurons (22,23). *RUNX3* is the smallest member of the RUNX family and is prototypical for the tumor suppressive potential of these proteins (24). For example, lower levels of *RUNX3* have been shown to be causally associated with human cancers for stomach (25), bladder (26) and colon (27). Recently, *RUNX3* was also identified as one of the five most informative genes for the CpG island methylator phenotype of colorectal cancer (28).

Because p53 and RUNX3 both control cell cycle progression and apoptotic processes (25,29,30), we postulate that these two proteins may be controlled by the same inhibitory pathway. Our results demonstrate that RUNX3 is stabilized by oncogenic Ras dependent induction of the p14^{ARF}-MDM2 pathway. MDM2 interacts with RUNX3 and suppresses the transcriptional activity of RUNX3 activity by blocking its trans-activation potential, as well as by facilitating MDM2-mediated ubiquitination and nuclear exclusion of RUNX3. Our data reveal that RUNX3 and p53 are both connected to the MDM2 pathway. This key finding indicates that the MDM2 pathway simultaneously controls two major tumor suppressor pathways with ubiquitous (p53) and lineage-specific (RUNX3) functions.

MATERIALS AND METHODS

Plasmids and antibodies

Full length cDNA, as well as serial deletion and point mutants of, respectively, *RUNX3* (NM_004350), *MDM2* (NM_002392) and *p14^{ARF}* (NM_000077) were amplified by PCR and subcloned into pCS4-3Myc or pCS4-3HA. Anti-RUNX3 (5G4) and anti-MDM2 (SMP14, D-12) antibodies were purchased from Abcam (UK) and Santa Cruz Biotechnology (CA, USA), respectively.

Cell culture and Transfection

Human embryonic kidney cells (HEK-293) and HeLa cells were maintained in Dulbecco's modified Eagle's medium and MKN45 was maintained in RPMI (Gibco BRL, CA, USA) supplemented with 10% fetal bovine serum (Gibco BRL) and 100 units/ml penicillin-streptomycin (Gibco BRL) at 37°C in a humidified atmosphere with 5% CO₂. Cell lines were obtained from Korea Research Institute of Bioscience and Biotechnology (KRIBB). Transient transfection was carried out using Lipofectamine Plus reagent (Invitrogen) according to the manufacturer's instruction. The siRNA for *MDM2* (si-MDM2: 5'-UUACAGCACCAUCAGUAGGUACAGA-3') (Invitrogen) and *RUNX3* (si-RX3-1; 5'-AACCUGAUGCCAUGACUC-3' & si-RX3-2; 5'-UGUUCUCAAACCAUCUCU G-3') (Bioneer, South Korea) were used for knock down *MDM2* or *RUNX3*, respectively. Reporter assays, immuno-precipitation and immuno-blotting analysis were performed as described previously (29).

In vitro ubiquitination assay

GST-MDM2 and His-tagged *Runt domain* were over-expressed in *Escherichia coli* BL21(DE3) and purified according to standard procedures. Ubiquitination assays were carried out by adding 20 ng each of human recombinant Ubiquitin Activating Enzyme (E1), Ubiquitin conjugating enzyme GST-tagged UbcH5b (E2), HA-tagged ubiquitin and 300 ng of purified GST-MDM2, 100–400 ng of His-Runt domain in ubiquitination reaction buffer (50mM HEPES pH7.4, 2.5mM pre-coupled Mg-ATP solution, 0.5mM PMSF). Reactions were carried out for 2hr at 37 °C.

Apoptosis assay by Annexin V staining

HEK-293 cells were treated with *RUNX3* specific siRNA (si-RX3-1 or si-RX3-2) or nonspecific siRNA (si-con) at 50 nM with Lipofectamine RNAiMAX (invitrogen). Twenty-four hours after siRNA treatment, the cells were transfected with *RUNX3* and/or *K-Ras-V12* expression plasmid and incubated in serum-free DMEM for 4 hours. The medium was changed with 0.5% FBS DMEM and further cultured 44 hours. The cells were harvested and treated with Annexin-V-FITC and Propidium iodide (PI) according to the manufacturer's instruction (FITC Annexin V apoptosis detection Kit1 cat# 556547, BD Biosciences, Pharmingen) and analyzed by flow cytometry using BD FACS caliber (BD Biosciences, Pharmingen).

RESULTS

Ras-activation elevates RUNX3 protein levels

Activating *K-Ras* mutations are known to modulate the p14^{ARF}-MDM2 pathway. We examined whether an activated *Ras* mutant controls RUNX3 protein expression. Human embryonic kidney (HEK-293) cells were transfected with a *K-Ras* mutant that is constitutively activated by a Val 12 mutation or an inactivating Asn 17 mutation. Increased expression of *K-Ras-V12* results in a dose-dependent increase in RUNX3 protein levels, but no increase in RUNX3 protein is observed with the *Ras-17N* mutant (Fig. 1A). Dose-dependent increases in the levels of endogenous RUNX3 protein and known transcriptional targets of RUNX3, *p21^{WAF/CIP}* and *Bim*, were also observed upon exogenous expression of *K-Ras-V12* (Fig. 1B). The induction of *p21* and *Bim* by *K-Ras-V12* did not occur when *RUNX3* was depleted by *RUNX3* siRNAs knock-down, suggesting an essential role for RUNX3 in the *K-Ras-V12*-dependent induction of *p21* and *Bim* (Supplementary Fig. 1). The increase of RUNX3 protein level appears to be independent from *RUNX3* transcription, because *RUNX3* mRNA levels are not affected by the expression of *K-Ras-V12* (Fig. 1B).

Because all three Runx proteins induce a senescence-like growth arrest in primary MEFs in response to activated Ras (31), we examined whether the levels of RUNX1 and RUNX2 are also increased by K-Ras-V12. Interestingly, however, the levels of the RUNX3 homologs, RUNX1 and RUNX2, were not increased by *K-Ras-V12* expression (Supplementary Fig. 2) in HEK-293 cells. This result suggests that RUNX3 is a specific target of *K-Ras-V12* at least in HEK-293 cells, and the molecular basis for this selectivity remains to be resolved. We next examined involvement of p14^{ARF} in the *K-Ras-V12*-induced increase of RUNX3 levels. Forced expression of *K-Ras-V12* or p14^{ARF} in A549 lung cancer cells, which do not express p14^{ARF}, increases RUNX3 only modestly and expression of both genes further increased the levels of RUNX3 protein (Fig. 1C).

Annexin V-FITC and Propidium iodide staining followed by flow cytometric analysis revealed that transient expression of *K-Ras-V12* or *RUNX3* alone in HEK-293 cells increased the number of apoptotic cells to twice that of mock treated cells (Fig. 1D). Co-expression of *K-Ras-V12* and *RUNX3* further increased the number of apoptotic cells by about two-fold. Importantly, treatment of *RUNX3* siRNA abolished the increase of apoptosis by *K-Ras-V12* (Fig. 1D). Knock-down of *RUNX3* by specific siRNAs is shown in Supplementary Fig. 1. These data together suggest that RUNX3 is a component of an oncogene surveillance pathway that prevents pathological consequences of abnormal oncogene activation.

MDM2 interacts with RUNX3

Because the predicted effect of elevating p14^{ARF} is inhibition of MDM2, the E3 ubiquitin ligase which is the principal attenuator of p53 protein levels (32), we postulated that MDM2 may also directly minimize protein expression of RUNX3 through physical interactions between RUNX3 and MDM2. We co-expressed epitope-tagged HA-RUNX3 or HA-p53 and Flag-MDM2 proteins in HEK-293 followed by co-immuno-precipitation and immunoblotting (IP-Western blot analysis). The results show that MDM2 is present in immunoprecipitates obtained with anti-HA (RUNX3) antibody (Fig. 2A). Comparable amounts of MDM2 are detected in anti-HA (p53) precipitates suggesting that MDM2 physically interacts with both RUNX3 and p53 (Fig 2A). The interactions between endogenously expressed RUNX3 and MDM2 were examined in HEK-293 cells that produce two main MDM2 isoforms (90 kDa and 75 kDa). Lysates were analyzed by immuno-precipitation with a specific RUNX3 monoclonal antibody (5G4) followed by immuno-blotting with anti-MDM2 or anti-RUNX3 antibody. The results establish that both MDM2 isoforms co-immuno-precipitate with RUNX3 (Fig. 2B), indicating that endogenous RUNX3 interacts with endogenous MDM2.

MDM2 down regulates RUNX3 protein levels

We investigated whether MDM2 levels are inversely correlated not only with the levels of p53 but also with that of RUNX3. Epitope-tagged HA-RUNX3 or HA-p53 were each co-expressed with increasing amounts of Flag-MDM2 in HEK-293 cells and the levels of the expressed proteins were monitored by immuno-blotting. Strikingly, expression of MDM2 protein decreases the levels of both p53 and RUNX3 (Fig. 2C). The complementary experiment in which MDM2 is depleted by siRNA administration reveals that a reduction in MDM2 increases endogenous RUNX3 protein levels in both MKN45 gastric carcinoma cells and HEK-293 cells (Fig. 2D).

The acidic domain of MDM2 mediates direct interactions with the Runt-homology domain of RUNX3

To delineate the domains of RUNX3 and MDM2 that are required for the interaction between the two proteins, serial deletion mutants of RUNX3 and MDM2 were examined by

IP-Western blot analysis (Supplementary Figs. 3A and 3C). Deletion of the RUNX3 C-terminal region beyond amino acid 234 or the N-terminal region before amino acid 110 does not diminish binding to MDM2 (Supplementary Fig. 3B). However, removal of C-terminal region beyond amino acid 187 increased MDM2 binding. Deletion of the highly conserved Runt-homology domain between amino acids 54 and 187 abolishes interactions with MDM2. Taken together, these results indicate that the distal region of the Runt-homology domain (amino acids 110 to 187) is essential for the RUNX3/MDM2 interaction and amino acids 187 to 234 inhibits the binding.

Complementary IP-Western blot experiments were performed with full length RUNX3 and MDM2 protein deletion mutants to define the domain of MDM2 that interacts with RUNX3. Deletion mutants encompassing the acidic domain of MDM2 were capable of binding full-length RUNX3, but deletion mutants lacking this domain were not (Supplementary Fig. 3C and 3D). This result suggests that the acidic domain of MDM2 is essential for binding to RUNX3. Notably, deletion of N-terminal region, which interacts with p53, is dispensable for the MDM2/RUNX3 interactions. Thus, MDM2 interacts with p53 and RUNX3 through separate regions.

Because CBF β , a heterodimeric partner of all three RUNX proteins, recognizes the conserved Runt domain, we examined whether CBF β interferes with the interaction between RUNX3 and MDM2. Expression of fixed amounts of *RUNX3* and *MDM2* and progressively increasing amounts of *CBF β 2* followed by IP-Western analysis revealed that CBF β 2 does not interfere with the RUNX3-MDM2 interaction (Supplementary Fig. 4).

MDM2 ubiquitinates RUNX3

The RING finger domain of MDM2 represents the active site for its E3 ubiquitin ligase activity and mediates the ubiquitination of MDM2 itself and the pRB and p53 tumor suppressors (33). To determine whether RUNX3 is also a target of the E3 ubiquitin ligase activity of MDM2, we performed *in vivo* ubiquitination assays. A mutant MDM2 protein (C438A) that lacks ubiquitin ligase activity was used as a negative control. Flag-tagged wild type and C438A mutant MDM2 proteins were co-expressed with Myc-RUNX3 and HA-Ub. IP-Western analysis results reveal that wild type MDM2 efficiently ubiquitinates RUNX3, but ubiquitination of RUNX3 by the MDM2(C438A) mutant is severely reduced (Fig. 3A). The ubiquitination activity of MDM2 on RUNX3 was further examined under physiological conditions by a loss-of-function approach. MKN45 cells were treated with siRNA for *MDM2* or a non-silencing RNA as control. Ubiquitination of endogenous RUNX3 is evident under control conditions, but decreased upon siRNA-mediated knock down of MDM2 protein (Fig. 3B). Because p14^{ARF} is a key negative regulator of MDM2, we tested whether p14^{ARF} inhibits MDM2-mediated RUNX3 ubiquitination. The result revealed that MDM2-mediated ubiquitination of RUNX3 is significantly reduced upon co-expression of p14^{ARF} (Fig. 3C). These results suggest that RUNX3 is a direct target of E3-ubiquitin ligase activity of MDM2 and p14^{ARF} negatively regulates MDM2-mediated RUNX3 ubiquitination.

RUNX3 protein is ubiquitinated by MDM2 at Lys-94 and Lys-148

MDM2 conjugates ubiquitin on lysine residues within its target proteins. To define the location of key lysine residues that modulate RUNX3 stability, we examined which RUNX3 deletion mutants are degradable by MDM2. RUNX3 protein deletion mutants were expressed with or without MDM2 and steady-state protein levels were measured by immuno-blotting (Fig. 4A). Full length RUNX3 as well as all other deletion mutants including a mutant protein containing only the N-terminal domain from amino acids 1 to 187 was still down regulated by coexpression of MDM2 protein. Although RUNX3(1–187) interacts with MDM2 more strongly than wild type RUNX3 or several deletion mutants, this

increased binding does not correlate with increased MDM2-mediated degradation. This result suggests that the C-terminal region of RUNX3 beyond aa 187 may be required for efficient MDM2-mediated RUNX3 degradation.

We deduced that lysines required for MDM2-mediated ubiquitination are located within the Runt-homology domain. To verify this assumption, we examined whether the Runt-homology domain is ubiquitinated *in vitro*. Ubiquitination analysis using a purified recombinant His-tagged protein spanning the Runt-homology domain of RUNX3 (His-RD) reveals that the Runt-homology domain is ubiquitinated by MDM2, as reflected by a distinct mobility shift (Fig. 4B). Unlike *in vivo* assays that exhibit poly-ubiquitination, *in vitro* assays only permit mono-ubiquitination on each lysine residue (34). Calculation of the relative molecular mass of the Runt-homology domain (~17 kDa) and the corresponding ubiquitinated form (~39 kDa) reveals that the difference in the two bands is about 22 kDa. Because ubiquitin has a molecular mass of ~8.5 kDa, the size difference suggests that ubiquitination of RUNX3 occurs at either two or three sites.

To pinpoint lysine (K) residues responsible for ubiquitination of RUNX3, we substituted the five lysine residues located within the Runt-homology domain to arginines. At least three of these residues (K94, K129 and K148) are located on the surface of the protein, based on the three dimensional structure of the Runt domain (35). Full-length wild type and lysine mutant RUNX3 were each co-expressed together with MDM2 in HEK-293 cells and sensitivity to MDM2-mediated degradation was examined. The results show that the single lysine mutant K94R is more resistant to MDM2-mediated degradation than lysine mutant K148R, while the K129R mutant is as sensitive as the wild type RUNX3 protein (Fig. 4C). Combination of the K94R and K148R mutations (double mutant K94R/K148R) generates a stable protein that is more resistant than the single mutant K94R. Importantly, triple mutation of the three remaining lysine residues within the Runt-homology domain (K129R/K186R/K192R) results in a protein that is as sensitive to MDM2 dependent destabilization as the wild type RUNX3 protein. Taken together, we conclude that K94 and K148 are key target residues for ubiquitination and K94 may represent the primary site.

We validated the importance of K94 and K148 in regulation of RUNX3 protein levels by *in vivo* ubiquitination analysis in HEK-293 cells. Mutation of K94 (K94R mutant) virtually abolishes ubiquitination by MDM2, while a single mutation of K148 (K148R mutant) merely reduces ubiquitination and mutation of K129 (K129R mutant) has no discernible effect (Fig. 4D). These results suggest that ubiquitination occurs primarily on K94 and secondarily on K148 of RUNX3. It is possible that the two modification events are linked and that ubiquitination of K94 may be required for the second ubiquitination at K148.

MDM2 suppresses the transcriptional activity of RUNX3

MDM2 inhibits p53-mediated transcriptional activity by direct binding to the DNA-binding motif of p53 and by ubiquitination of p53, which results in nuclear export to the cytoplasm. We therefore investigated whether MDM2 down-regulates RUNX3-mediated transcriptional activity using the RUNX3 responsive *p21^{Cip/Waf}* promoter fused to the luciferase reporter gene (29). We find that the transactivation activity of RUNX3 is suppressed by MDM2 in a dose-dependent manner (Fig. 5A). Interestingly, the suppression of RUNX3 activity by MDM2 is released by the co-expression of p14^{ARF} (Fig. 5B). Reporter gene assays reveal that mutant MDM2(C438A), which lacks ubiquitin ligase activity, also inhibits RUNX3 stimulation of *p21* promoter activity, although less effectively than wild type MDM2 (Fig. 5C). This result suggests that the transcriptional activity of RUNX3 is controlled by MDM2 through an ubiquitination-independent mechanism. Consistent with this interpretation, the trans-activating activity of the ubiquitination-defective mutant RUNX3-K94R is also suppressed by MDM2, although not to the same extent as wild type RUNX3 (Fig. 5D).

Collectively, these results suggest that, similar to p53, RUNX3 is inactivated by MDM2 by both ubiquitination-dependent destabilization and ubiquitination-independent interference with transcriptional activation.

MDM2 facilitates nuclear export of RUNX3

MDM2 induces nuclear export of p53, which subsequently leads to the degradation of the protein. To investigate the possibility that MDM2 also facilitates nuclear exclusion of RUNX3, we transiently transfected Myc-RUNX3 and Flag-MDM2 proteins in HeLa cells and analyzed the subcellular localization of RUNX3 by immuno-fluorescence microscopy. RUNX3 or MDM2 alone are each exclusively localized in the nucleus (Fig. 6A), corroborating previous studies (36). However, when both genes are expressed within the same cell, RUNX3 becomes localized in the cytoplasm indicating export from the nucleus (Fig. 6B). However, an ubiquitination-defective MDM2 mutant (MDM2-339; see Supplementary Fig. 3), which lacks the RING finger domain, fails to translocate RUNX3 to cytoplasm (Fig. 6C). Hence, the E3-ubiquitin ligase activity of MDM2 is required for the cytoplasmic sequestration of RUNX3. Consistent with this observation, wild type MDM2 fails to translocate the ubiquitination-defective mutant RUNX3-K94R to the cytoplasm (Fig. 6D). Fractionated nuclear and cytoplasmic proteins from transfected cells expressing RUNX3 and MDM2 or MDM2-339 were examined by IB analysis. The results confirmed that MDM2 but not MDM2-339 facilitates cytoplasmic localization of RUNX3 (data not shown). Taken together, these results indicate that MDM2 induces nuclear export of RUNX3 through ubiquitination. We conclude that MDM2 controls RUNX3 through the same mechanisms as documented for p53.

DISCUSSION

RUNX3 is a tumor suppressor and inactivation of its nuclear function is prevalent in various tumors. Here we provide insight into a key mechanism by which RUNX3 exerts its biological functions. Our data indicate that RUNX3 is a principal lineage-specific component of the p14^{ARF}-MDM2 oncogenic surveillance pathway thus clarifying how deregulation of RUNX3 activity is linked to cancer susceptibility.

Unlike the ubiquitously expressed p53 protein, *RUNX3* is expressed in distinct tissues and regulate cell growth and differentiation in a lineage-specific manner. However, *RUNX3* has also many similarities with *p53*. For example, *RUNX3* and *p53* are very frequently inactivated in various kinds of tumors and the frequencies are about 50% (25,37). Both RUNX3 and p53 are DNA binding transcription factors that directly control the cell cycle and apoptosis (25). Both exert their growth suppressive effects by regulating analogous molecular pathways; RUNX3 is associated with its ability to induce cell cycle arrest and programmed cell death by transcriptional up-regulation of the CDK inhibitor *p21^{CIP/WAF1}* (29) and the apoptotic regulator *Bim* (*Bcl2L11*) (30), respectively, and p53 also controls *p21^{CIP/WAF1}* and apoptotic mediators.

Although the p53 pathway has a major role in the cellular protection mechanisms that prevent pathological consequences of abnormal oncogenic stimulation (4), this pathway often fails to respond to oncogene activation during cancer development. For example, *K-Ras* codon 12 mutation is frequently found at pre-neoplastic stages of lung adenocarcinoma but p53 null mutations are found at even later stages (38,39). This result suggests that there are p53-independent surveillance mechanisms that guard against unscheduled mitogenic cues. Interestingly, RUNX3 is frequently down regulated in pre-neoplastic human lung adenocarcinomas (40). This result could possibly suggest that inactivation of RUNX3 may be involved in p53-independent oncogene surveillance mechanisms.

In this study, we investigated how and when RUNX3 is activated and found that RUNX3 can be activated through 14^{ARF}-MDM2 pathway when *Ras* is abnormally activated. In normal conditions, MDM2 inactivates the transactivation activity of RUNX3 through protein/protein interactions, as well as mediates ubiquitination of RUNX3 that stimulates nuclear export and subsequent degradation of RUNX3. Proteasomal degradation of p53 is a staged event in which MDM2 and other E3 ubiquitin ligases (e.g., COP1 and Pirh2) ubiquitinate p53 sequentially (41,42). MDM2 stimulates nuclear export of p53 mainly through mono-ubiquitination or bi-ubiquitination (43,44). Our results show that MDM2 promotes nuclear export of RUNX3. Similar to p53, MDM2 may support mono-ubiquitination of Runx3 in the nucleus, thus promoting nuclear export and cytoplasmic poly-ubiquitination by other ubiquitin E3 ligases prior to proteasomal delivery.

The N-terminal region of MDM2 directly binds to p53 and inhibits transactivation by p53. This activity is independent of the ability of MDM2 to reduce p53 levels through its C-terminal enzymatic domain (5). We found that MDM2 also inhibits RUNX3-mediated transcriptional activity in a concentration dependent manner, even if the ubiquitin-conjugating activity of MDM2 is compromised (C438A mutant). Thus, analogous to p53, MDM2 can inhibit RUNX3 activity through two separate functions: it promotes degradation of RUNX3 and can block transcriptional activation. Our data show that one key difference between p53 and RUNX3 is that the latter binds to the acidic domain of MDM2, a region that is adjacent to the N-terminal domain of MDM2 that interacts with p53 and pRB (45,46).

The p14^{ARF}-MDM2-p53 pathway is subject to p53 dependent feed-back regulation and resembles a molecular oscillator. *MDM2* gene transcription is activated by p53 as a normal part of the mechanisms that resolves a p53 dependent growth arrest in response to DNA damage or oncogenic stimuli. The linkage of this pathway to RUNX3 indicates that p53 can indirectly control RUNX3 levels. In conclusion, our results suggest involvement of RUNX3 in oncogene surveillance and a remarkable dual role for MDM2 in attenuating the levels of p53 and RUNX3 as principal tumor suppressors.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by a Creative Research Grant (Grant number: R16-2003-002-01001-02006) from the Korea Science and Engineering Foundation (to S.C.B.) and in part by NIH grants R01-AR49069 (to A.v.W.) and P01-CA082834 (to G.S.S.). We thank Jane Lian and Janet Stein for stimulating discussions.

REFERENCES

1. Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. *Nat Rev Cancer*. 2005; 5:376–387. [PubMed: 15864279]
2. Bartek J, Lukas J. Mammalian G1- and S-phase checkpoints in response to DNA damage. *Curr Opin Cell Biol*. 2001; 13:738–747. [PubMed: 11698191]
3. Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. *Mol Cell*. 2006; 21:307–315. [PubMed: 16455486]
4. Efeyan A, Serrano M. p53: guardian of the genome and policeman of the oncogenes. *Cell Cycle*. 2007; 6:1006–1010. [PubMed: 17457049]
5. Leng P, Brown DR, Shivakumar CV, Deb S, Deb SP. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation. *Oncogene*. 1995; 10:1275–1282. [PubMed: 7731677]

6. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. *Cancer Res.* 1994; 54:794–799. [PubMed: 8306343]
7. Zou M, Shi Y, al-Sedairy S, Hussain SS, Farid NR. The expression of the MDM2 gene, a p53 binding protein, in thyroid carcinogenesis. *Cancer.* 1995; 76:314–318. [PubMed: 8625108]
8. Dubs-Poterszman MC, Tocque B, Wasylyk B. MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. *Oncogene.* 1995; 11:2445–2449. [PubMed: 8570197]
9. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. *Nat Med.* 1996; 2:912–917. [PubMed: 8705862]
10. Ito Y. Oncogenic potential of the RUNX gene family: 'overview'. *Oncogene.* 2004; 23:4198–4208. [PubMed: 15156173]
11. van Wijnen AJ, Stein GS, Gergen JP, et al. Nomenclature for Runt-related (RUNX) proteins. *Oncogene.* 2004; 23:4209–4210. [PubMed: 15156174]
12. Look AT. Oncogenic transcription factors in the human acute leukemias. *Science.* 1997; 278:1059–1064. [PubMed: 9353180]
13. Osato M, Asou N, Abdalla E, et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. *Blood.* 1999; 93:1817–1824. [PubMed: 10068652]
14. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. *Nat Rev Cancer.* 2002; 2:502–513. [PubMed: 12094236]
15. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. *Cell.* 1997; 89:755–764. [PubMed: 9182763]
16. Otto F, Thornell AP, Crompton T, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. *Cell.* 1997; 89:765–771. [PubMed: 9182764]
17. Lee B, Thirunavukkarasu K, Zhou L, et al. Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. *Nat Genet.* 1997; 16:307–310. [PubMed: 9207800]
18. Mundlos S, Otto F, Mundlos C, et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. *Cell.* 1997; 89:773–779. [PubMed: 9182765]
19. Thomas DM, Johnson SA, Sims NA, et al. Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. *J Cell Biol.* 2004; 167:925–934. [PubMed: 15583032]
20. Taniuchi I, Osato M, Egawa T, et al. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. *Cell.* 2002; 111:621–633. [PubMed: 12464175]
21. Woolf E, Xiao C, Fainaru O, et al. Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. *Proc Natl Acad Sci U S A.* 2003; 100:7731–7736. [PubMed: 12796513]
22. Inoue K, Ozaki S, Shiga T, et al. Runx3 controls the axonal projection of proprioceptive dorsal root ganglion neurons. *Nat Neurosci.* 2002; 5:946–954. [PubMed: 12352981]
23. Levanon D, Bettoun D, Harris-Cerruti C, et al. The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons. *EMBO J.* 2002; 21:3454–3463. [PubMed: 12093746]
24. Bae SC, Choi JK. Tumor suppressor activity of RUNX3. *Oncogene.* 2004; 23:4336–4340. [PubMed: 15156190]
25. Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. *Cell.* 2002; 109:113–124. [PubMed: 11955451]
26. Kim WJ, Kim EJ, Jeong P, et al. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. *Cancer Res.* 2005; 65:9347–9354. [PubMed: 16230397]
27. Ito K, Lim AC, Salto-Tellez M, et al. RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. *Cancer Cell.* 2008; 14:226–237. [PubMed: 18772112]

28. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. *Nat Genet.* 2006; 38:787–793. [PubMed: 16804544]
29. Chi XZ, Yang JO, Lee KY, et al. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. *Mol Cell Biol.* 2005; 25:8097–8107. [PubMed: 16135801]
30. Yano T, Ito K, Fukamachi H, et al. The RUNX3 Tumor Suppressor Upregulates Bim in Gastric Epithelial Cells Undergoing Transforming Growth Factor {beta}-Induced Apoptosis. *Mol Cell Biol.* 2006; 26:4474–4488. [PubMed: 16738314]
31. Kilbey A, Terry A, Cameron ER, Neil JC. Oncogene-induced senescence: an essential role for Runx. *Cell Cycle.* 2008; 7:2333–2340. [PubMed: 18677118]
32. Fuchs SY, Adler V, Buschmann T, Wu X, Ronai Z. Mdm2 association with p53 targets its ubiquitination. *Oncogene.* 1998; 17:2543–2547. [PubMed: 9824166]
33. Honda R, Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. *Oncogene.* 2000; 19:1473–1476. [PubMed: 10723139]
34. Lai Z, Ferry KV, Diamond MA, et al. Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization. *J Biol Chem.* 2001; 276:31357–31367. [PubMed: 11397792]
35. Tahirov TH, Inoue-Bungo T, Morii H, et al. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta. *Cell.* 2001; 104:755–767. [PubMed: 11257229]
36. Gu J, Nie L, Kawai H, Yuan ZM. Subcellular distribution of p53 and p73 are differentially regulated by MDM2. *Cancer Res.* 2001; 61:6703–6707. [PubMed: 11559539]
37. Kim TY, Lee HJ, Hwang KS, et al. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. *Lab Invest.* 2004; 84:479–484. [PubMed: 14968123]
38. Slebos RJ, Baas IO, Clement MJ, et al. p53 alterations in atypical alveolar hyperplasia of the human lung. *Hum Pathol.* 1998; 29:801–808. [PubMed: 9712420]
39. Cazorla M, Hernández L, Fernández PL, et al. Ki-ras gene mutations and absence of p53 gene mutations in spontaneous and urethane-induced early lung lesions in CBA/J mice. *Mol Carcinog.* 1998; 21:251–260. [PubMed: 9585255]
40. Licchesi JD, Westra WH, Hooker CM, Machida EO, Baylin SB, Herman JG. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. *Carcinogenesis.* 2008; 29:895–904. [PubMed: 18308762]
41. Dornan D, Wertz I, Shimizu H, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. *Nature.* 2004; 429:86–92. [PubMed: 15103385]
42. Leng RP, Lin Y, Ma W, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. *Cell.* 2003; 112:779–791. [PubMed: 12654245]
43. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. *Science.* 2003; 302:1972–1975. [PubMed: 14671306]
44. Oh W, Lee EW, Sung YH, et al. Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2. *J Biol Chem.* 2006; 281:17457–17465. [PubMed: 16624822]
45. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. *Mol Cell Biol.* 1993; 13:4107–4114. [PubMed: 7686617]
46. Sdek P, Ying H, Zheng H, et al. The central acidic domain of MDM2 is critical in inhibition of retinoblastoma-mediated suppression of E2F and cell growth. *J Biol Chem.* 2004; 279:53317–53322. [PubMed: 15485814]

Figure 1. Ras-activation elevates RUNX3 protein levels

(A) *Flag-RUNX3* was coexpressed with progressively increasing amounts of *Myc-K-Ras-V12* or *Myc-K-Ras-17N* in HEK-293 cells as indicated and the levels of RUNX3 (RX3) and K-Ras were measured by immuno-blotting with anti-Flag or anti-Myc antibody. Tubulin (Tub) was immuno-blotting with anti-tubulin antibody for loading control.

(B) Progressively increasing amounts of *Myc-K-Ras-V12* were expressed in HEK-293 cells and the levels of endogenous RUNX3, p21^{WAF/CIP} and Bim were assessed by immuno-blotting with anti-RUNX3, anti-p21^{WAF/CIP} and anti-Bim antibody, respectively, and the levels of *RUNX3* mRNA were monitored by Northern blotting.

(C) Serially increasing amounts of *Myc-K-Ras-V12* were expressed with or without *HA-p14^{AFR}* (250 ng) in A549 lung cancer cells which lack endogenous p14^{AFR}. Endogenous level of RUNX3 was measured by anti-RUNX3 antibody

(D) HEK-293 cells were transiently transfected with *Myc-RUNX3*, *Myc-K-Ras-V12* and/or *RUNX3* specific siRNAs. After 48 hours transfection the cells were stained with Annexin V-FITC and Propidium Iodide. Apoptotic cells were detected by flow cytometry. The percentages of early apoptotic cells (Annexin V-FITC positive/PI negative; lower right quadrant) and late apoptotic and necrotic cells (Annexin V-FITC positive/PI positive; upper right quadrant) are shown. The results are summarized as a bar graph at the bottom. The error bars indicate the standard deviation of the results of three independent experiments.

Figure 2. MDM2 physically interact with RUNX3 and down regulates its protein level

(A) *Flag-MDM2* was coexpressed with *HA-RUNX3* (*HA-RX3*) or *HA-p53* in HEK-293 cells and cell lysates (500 μ g) were immunoprecipitated (IP) with anti-HA antibody and immunoblotted (IB) with anti-Flag antibody. Expression of transfected genes were detected by immuno-blotting with anti-HA or anti-Flag antibody.

(B) Cell lysate (1 mg) was obtained from MKN45 cells and immuno-precipitated with anti-RUNX3 monoclonal antibody (5G4) or IgG. The immuno-precipitate was analyzed by immuno-blotting using anti-MDM2 antibody or anti-RUNX3 antibody. Input: 50 μ g of cell lysate for control.

(C) HEK-293 cells were transiently transfected with fixed amount of *HA-RUNX3* (0.4 μ g) or *HA-p53* (0.4 μ g) with an increasing amount of *Flag-MDM2* (0, 1.0 and 2.0 μ g). The protein expression levels were analyzed by immuno-blotting using anti-HA or Flag antibody. The intensity of each band was quantitated by densitometry and the relative ratios are indicated.

(D) MKN45 and HEK-293 cells were treated with *siMDM2* and the endogenous levels of MDM2 and RUNX3 was examined by immuno-blotting using anti-MDM2 antibody or anti-RUNX3 antibody.

Figure 3. MDM2 facilitates ubiquitination of RUNX3 *in vivo*

(A) *Flag-MDM2* or mutant *MDM2(C438A)* was coexpressed with *Myc-RUNX3* and *HA-Ubiquitin (HA-Ub)* in HEK-293 cells as indicated. Cell lysates (500 μ g for each reaction) were immuno-precipitated with anti-Myc (RUNX3) antibody and analyzed by immunoblotting with anti-HA (Ub) antibody. WT: wild type.

(B) MKN45 cells were transfected with *HA-Ub* and *MDM2* specific siRNA and the ubiquitination of endogenous RUNX3 was measured by IP with anti-RUNX3 antibody and IB with anti-HA (Ub) antibody.

(C) *Flag-MDM2* (WT) or *Flag-MDM2(C438A)* (mt) was coexpressed with *Myc-RUNX3*, *HA-Ub* and *HA-p14^{ARF}* as indicated. Cell lysates (500 μ g for each reaction) were immuno-

precipitated with anti-Myc (RUNX3) antibody and analyzed by immuno-blotting with anti-HA (Ub) antibody.

Figure 4. Identification of ubiquitination sites

(A) *Myc-RUNX3* and its serial deletion constructs were coexpressed with *Flag-MDM2* in HEK-293 cells as indicated. Expression levels of transfected genes were measured by immuno-blotting with anti-Myc or anti-Flag antibody.

(B) Purified GST-MDM2 and His-Runt domain (His-RD; aa 64–190) were mixed with E1, E2 and HA-Ub as indicated for *in vitro* ubiquitination. His-RD was analyzed by SDS-gel electrophoresis followed by immuno-blotting with anti-His antibody.

(C) Wild type *RUNX3* and its lysine to arginine mutants (K94R, K129R, K148R, K94/148R and K129,186,192) were expressed with or without *MDM2* and the protein levels were analyzed by IB using anti-Myc (*RUNX3*) and anti-Flag (*MDM2*) antibodies.

(D) *Myc-RUNX3* and its mutants (K94R, K129R and K148R) and *HA-Ub* were co-expressed with or without *Flag-MDM2*. *RUNX3* ubiquitination was measured by IP with anti-Myc (*RUNX3*) antibody followed by IB with anti-HA (Ub) antibody.

Figure 5. MDM2 inhibits RUNX3-mediated transcriptional activity

(A) HEK-293 cells were transfected with a fixed amount of *RUNX3* (200 ng), and increasing amount of *MDM2* (100 ng, 250 ng and 500 ng as indicated). The effect of MDM2 on the transactivation activity of RUNX3 was measured by the luciferase reporter assay.

(B) Cells were transfected with fixed amount of *RUNX3* (200 ng) and *MDM2* (400 ng) and increasing amount of *p14^{ARF}* (200 ng and 400 ng as indicated). The effect of p14^{ARF} on the MDM2-mediated suppression of on the RUNX3 transactivation activity was measured by luciferase reporter assays.

(C) Cells were transfected with a fixed amount of *RUNX3* (200 ng) and increasing amount of either wild type *MDM2* (WT) or *MDM2*(C438A) (200 ng and 400 ng as indicated). The effect of the E3 ubiquitin ligase activity of MDM2 on RUNX3 transactivation activity was measured by the luciferase reporter assay.

(D) Cells were transfected with wild type *RUNX3* or lysine mutated *RUNX3* and *MDM2* as indicated. Mutation of three lysine residues (K129R/K186R/K192R) by itself abolished *RUNX3* transactivation activity. The effect of *RUNX3* ubiquitination on its transactivation activity was measured by luciferase reporter assays using *pGL3-p21* promoter-luciferase (50 ng) as reporter and *pCMV-β-gal* (50 ng) as internal control.

Figure 6. MDM2 facilitates nuclear export of RUNX3

HeLa cells were transfected with *Myc-RUNX3* and *Flag-MDM2* or their mutants. The subcellular localization of the expressed proteins was detected by immuno-fluorescent staining. Each nucleus was visualized by DAPI staining.

(A) Image of cells expressing *Myc-RUNX3* alone or *Flag-MDM2* alone. RUNX3 and MDM2 were detected exclusively in nucleus.

(B) Image of cells co-expressing *Myc-RUNX3* and *Flag-MDM2*. Substantial level of RUNX3 was detected in cytoplasm in cells expressing *MDM2*.

(C) Image of cells co-expressing *Myc-RUNX3* and *Flag-MDM2-339*. RUNX3 was detected only in the nucleus even in the cells expressing *MDM2-339*.

(D) Image of cells co-expressing *Myc-RUNX3-K94R* and *Flag-MDM2*. RUNX3-K94R was detected only in the nucleus even in the cells expressing wild type MDM2.